Liraglutide Fails to Protect Against Doxorubicin Heart Damage in Rats Despite Anti-Inflammatory Hopes
Two weeks of liraglutide pretreatment did not prevent doxorubicin-induced acute cardiotoxicity in rats, despite GLP-1 agonists' known anti-inflammatory and antioxidant properties.
Quick Facts
What This Study Found
Liraglutide pretreatment (0.6 mg/kg daily for 2 weeks) did not improve any echocardiographic, functional, or molecular measure of doxorubicin-induced acute cardiotoxicity in rats.
Key Numbers
60 male Wistar rats; 4 groups (15 per group); control, doxorubicin alone, liraglutide alone, doxorubicin + liraglutide.
How They Did This
Controlled animal study with 60 male Wistar rats in four groups (Control, Doxorubicin, Liraglutide, Doxorubicin+Liraglutide), with echocardiography, isolated heart studies, and myocardial protein expression analysis 48 hours after doxorubicin.
Why This Research Matters
This negative result is important — it tempers enthusiasm about repurposing GLP-1 agonists as cardioprotective agents during cancer chemotherapy and highlights that GLP-1's known anti-inflammatory effects don't necessarily translate to all types of cardiac injury.
The Bigger Picture
Negative studies are essential for evidence-based medicine. While GLP-1 agonists show cardiovascular benefits in many contexts, this study demonstrates they cannot protect against all forms of heart damage, helping define the boundaries of their cardioprotective potential.
What This Study Doesn't Tell Us
Acute single-dose doxorubicin model may not represent clinical protocols (which use multiple lower doses); only one liraglutide dose tested; 2-week pretreatment may be insufficient; rat model may not predict human response; 48-hour endpoint may miss delayed protective effects.
Questions This Raises
- ?Would longer liraglutide pretreatment or concurrent administration produce different results?
- ?Do other GLP-1 agonists (semaglutide, tirzepatide) show similar negative results against doxorubicin cardiotoxicity?
- ?Could GLP-1 agonists protect against chronic, lower-dose doxorubicin protocols used clinically?
Trust & Context
- Key Stat:
- No protection liraglutide failed to improve any measure of doxorubicin-induced cardiotoxicity
- Evidence Grade:
- Moderate preclinical evidence from a well-designed, adequately powered rat study. The negative finding is informative but limited by the acute high-dose doxorubicin model.
- Study Age:
- Published in 2024, contributing a negative result to the growing literature on GLP-1 cardioprotection.
- Original Title:
- Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats.
- Published In:
- International journal of molecular sciences, 25(11) (2024)
- Authors:
- Tonon, Carolina R, Monte, Marina G, Balin, Paola S, Fujimori, Anderson S S, Ribeiro, Ana Paula D, Ferreira, Natália F, Vieira, Nayane M, Cabral, Ronny P, Okoshi, Marina P, Okoshi, Katashi, Zornoff, Leonardo A M, Minicucci, Marcos F, Paiva, Sergio A R, Gomes, Mariana J, Polegato, Bertha F
- Database ID:
- RPEP-09396
Evidence Hierarchy
Frequently Asked Questions
Can liraglutide protect your heart from chemotherapy damage?
Not in this study. Despite liraglutide's known anti-inflammatory effects, it failed to prevent heart damage from doxorubicin in rats. This suggests GLP-1 medications' cardiovascular benefits don't extend to chemotherapy-related heart injury.
Why does this negative result matter?
Because there was hope that GLP-1 drugs could double as heart protectors during cancer treatment. This study shows that's not the case for acute doxorubicin exposure, helping clinicians avoid false assumptions about cross-purpose drug benefits.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09396APA
Tonon, Carolina R; Monte, Marina G; Balin, Paola S; Fujimori, Anderson S S; Ribeiro, Ana Paula D; Ferreira, Natália F; Vieira, Nayane M; Cabral, Ronny P; Okoshi, Marina P; Okoshi, Katashi; Zornoff, Leonardo A M; Minicucci, Marcos F; Paiva, Sergio A R; Gomes, Mariana J; Polegato, Bertha F. (2024). Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats.. International journal of molecular sciences, 25(11). https://doi.org/10.3390/ijms25115833
MLA
Tonon, Carolina R, et al. "Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats.." International journal of molecular sciences, 2024. https://doi.org/10.3390/ijms25115833
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-..." RPEP-09396. Retrieved from https://rethinkpeptides.com/research/tonon-2024-liraglutide-pretreatment-does-not
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.